Clinical Trial Update: Description of the Cystatin C as an Early Nephrotoxic Bio-marker in Pediatric Oncology [NA]

View source ↗

Summary

The trial update reports on evaluating cystatin C as an early biomarker of nephrotoxicity in pediatric oncology patients. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Diseases

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Kidney Diseases | NA | Status: COMPLETED